NASDAQ:VANI Vivani Medical Q2 2026 Earnings Report $1.23 -0.04 (-3.15%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.25 +0.02 (+1.30%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vivani Medical EPS ResultsActual EPS-$0.07Consensus EPS -$0.08Beat/MissBeat by +$0.01One Year Ago EPSN/AVivani Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVivani Medical Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time7:00AM ETUpcoming EarningsVivani Medical's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vivani Medical Earnings HeadlinesVivani Medical Announces Merger Deal Involving CortigentSeptember 16, 2026 | tipranks.comVivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor ConferencesSeptember 3, 2026 | quiverquant.comQHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its valuation has doubled since the announcement, with some estimates putting the company's worth near 3 trillion dollars by IPO day. Google, Amazon, Nvidia and Microsoft have all taken stakes, while Goldman Sachs, Morgan Stanley and JPMorgan are competing for private shares. Anthropic's annualized revenue reportedly grew 80 times in the first quarter alone. See how investors are positioning ahead of this closely watched IPO.September 24 at 1:00 AM | Weiss Ratings (Ad)Vivani Medical Announces Participation in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)August 20, 2026 | theglobeandmail.comVivani Medical Inc U5PAugust 19, 2026 | morningstar.comMSee More Vivani Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email. Email Address About Vivani MedicalVivani Medical (NASDAQ:VANI) (NASDAQ: VANI) is a biopharmaceutical company developing miniature, long-term implantable drug-delivery systems for chronic diseases. Its proprietary NanoPortal technology is designed to deliver medication continuously over extended periods, potentially reducing the need for frequent injections or daily dosing. The company’s pipeline has focused primarily on treatments based on glucagon-like peptide-1 (GLP-1) therapies. Its lead candidates have included NPM-115, an implantable formulation of exenatide being developed for chronic weight management, and NPM-119, an exenatide-based implant intended to treat type 2 diabetes. Vivani has also evaluated additional applications of its implant technology for other metabolic and chronic conditions. Vivani is headquartered in Fremont, California, and its development activities have primarily been directed toward the U.S. pharmaceutical and biotechnology market. The company originated from Nano Precision Medical, Inc. and became a publicly traded company through a business combination involving Second Sight Medical Products. Vivani is led by President and Chief Executive Officer Adam Mendelsohn, Ph.D.View Vivani Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
